COVID-19 mRNA booster vaccine induces transient CD8+ T effector cell responses while conserving the memory pool for subsequent reactivation.
Matthias ReinscheidHendrik LuxenburgerVivien KarlAnne GraeserSebastian GieseKevin CiminskiDavid B ReegValerie OberhardtNatascha RoehlenJulia Lang-MeliKathrin HeimNina GrossChristina BaumSiegbert RiegClaudius SpeerFlorian EmmerichSusanne BreisingerDaniel SteinmannBertram BengschTobias BoettlerGeorg KochsMartin SchwemmleRobert ThimmeChristoph Neumann-HaefelinMaike HofmannPublished in: Nature communications (2022)
Immunization with two mRNA vaccine doses elicits robust spike-specific CD8 + T cell responses, but reports of waning immunity after COVID-19 vaccination prompt the introduction of booster vaccination campaigns. However, the effect of mRNA booster vaccination on the spike-specific CD8 + T cell response remains unclear. Here we show that spike-specific CD8 + T cells are activated and expanded in all analyzed individuals receiving the 3 rd and 4 th mRNA vaccine shots. This CD8 + T cell boost response is followed by a contraction phase and lasts only for about 30-60 days. The spike-specific CD8 + T memory stem cell pool is not affected by the 3 rd vaccination. Both 4 th vaccination and breakthrough infections with Delta and Omicron rapidly reactivate CD8 + T memory cells. In contrast, neutralizing antibody responses display little boost effect towards Omicron. Thus, COVID-19 mRNA booster vaccination elicits a transient T effector cell response while long-term spike-specific CD8 + T cell immunity is conserved to mount robust memory recall targeting emerging variants of concern.
Keyphrases
- coronavirus disease
- sars cov
- stem cells
- working memory
- single cell
- emergency department
- cell therapy
- immune response
- magnetic resonance
- gene expression
- magnetic resonance imaging
- radiation therapy
- transcription factor
- mesenchymal stem cells
- cell death
- dna methylation
- neoadjuvant chemotherapy
- cell proliferation
- blood brain barrier
- cell cycle arrest
- dengue virus
- signaling pathway
- type iii
- smooth muscle